AYGEN, B. Et Al. 2020. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. TURKISH JOURNAL OF GASTROENTEROLOGY , vol.31, no.4 , 305-317.

AYGEN, B., DEMİRTÜRK, N., YILDIZ, O., ÇELEN, M. K., Celik, I., Barut, S., ... URAL, O.(2020). Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. TURKISH JOURNAL OF GASTROENTEROLOGY , vol.31, no.4, 305-317.

AYGEN, BİLGEHAN Et Al. "Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience," TURKISH JOURNAL OF GASTROENTEROLOGY , vol.31, no.4, 305-317, 2020

AYGEN, BİLGEHAN Et Al. "Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience." TURKISH JOURNAL OF GASTROENTEROLOGY , vol.31, no.4, pp.305-317, 2020

AYGEN, B. Et Al. (2020) . "Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience." TURKISH JOURNAL OF GASTROENTEROLOGY , vol.31, no.4, pp.305-317.

@article{article, author={BİLGEHAN AYGEN Et Al. }, title={Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience}, journal={TURKISH JOURNAL OF GASTROENTEROLOGY}, year=2020, pages={305-317} }